AviadoBio Appoints Graeme Fielder as Chief Operating Officer and Alex Bloom as Chief Technical Officer
October 04, 2022 07:00 ET
|
Aviadobio Ltd
AviadoBio Appoints Graeme Fielder as Chief Operating Officer and Alex Bloom as Chief Technical Officer London, UK; October 4, 2022 — AviadoBio, a pioneering, pre-clinical stage gene therapy company...
AviadoBio Appoints Dr. David Cooper as Chief Medical Officer
August 02, 2022 07:00 ET
|
Aviadobio Ltd
AviadoBio Appoints Dr. David Cooper as Chief Medical Officer A neurosurgeon with more than 20 years’ biopharmaceutical experience and proven expertise in gene therapy and rare diseasesHas supported...
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia
May 17, 2022 07:00 ET
|
Aviadobio Ltd
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia Intrathalamic...
AviadoBio Announces Formation of Scientific Advisory Board
May 12, 2022 07:00 ET
|
Aviadobio Ltd
AviadoBio Announces Formation of Scientific Advisory Board Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and...
AviadoBio Announces Formation of Scientific Advisory Board
May 12, 2022 02:00 ET
|
Aviadobio Ltd
AviadoBio Announces Formation of Scientific Advisory Board Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and...
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022
May 04, 2022 08:00 ET
|
Aviadobio Ltd
AviadoBio to Present Pre-clinical Data on its Gene Therapy Candidate for Frontotemporal Dementia at ASGCT 2022 Intrathalamic delivery of AVB-101 shows promising efficacy in a pre-clinical disease...
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
April 27, 2022 07:00 ET
|
Aviadobio Ltd
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia FDA and EC decisions reinforce severity of unmet...
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia
April 27, 2022 02:00 ET
|
Aviadobio Ltd
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia FDA and EC decisions reinforce severity of unmet...
AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform
December 02, 2021 02:00 ET
|
Aviadobio Ltd
AviadoBioTM Raises $80 million in Series A Financing to Advance Neurodegenerative Gene Therapy Platform Series A led by New Enterprise Associates (NEA) and co-led by Monograph Capital follows...